Prof James Catto from the University of Sheffield described the findings as a "major breakthrough" in treating bladder cancer ...
R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...
The most important take-home information from the INTERLACE trial is that in some people with cervical cancer that are ...
The Independent on MSN2d
‘Game changer’ immunotherapy drug could lead to increased survival rates for bladder cancer patientsThe study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...
Cancer is a disease of the genome, according to Dr. Elli Papaemmanuil, computational oncologist at MSK. By looking at the ...
Colorectal cancer (CRC) is a type of cancer that begins in the colon (large intestine) or rectum, which are parts of the ...
News Medical on MSN1d
New drug cocktail enhances CAR-T cells for cancer treatmentPreclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust ...
A new therapy for the most aggressive type of brain cancer can extend patients' survival while cutting the length of ...
Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...
5don MSN
Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback